Article

Predicting the in Vivo Mechanism of Action for Drug Leads Using NMR Metabolomics

ACS Chemical Biology (Impact Factor: 5.36). 01/2012; 7(1):166-71. DOI: 10.1021/cb200348m
Source: PubMed

ABSTRACT New strategies are needed to circumvent increasing outbreaks of resistant strains of pathogens and to expand the dwindling supply of effective antimicrobials. A common impediment to drug development is the lack of an easy approach to determine the in vivo mechanism of action and efficacy of novel drug leads. Toward this end, we describe an unbiased approach to predict in vivo mechanisms of action from NMR metabolomics data. Mycobacterium smegmatis, a non-pathogenic model organism for Mycobacterium tuberculosis, was treated with 12 known drugs and 3 chemical leads identified from a cell-based assay. NMR analysis of drug-induced changes to the M. smegmatis metabolome resulted in distinct clustering patterns correlating with in vivo drug activity. The clustering of novel chemical leads relative to known drugs provides a mean to identify a protein target or predict in vivo activity.

0 Followers
 · 
148 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Isonitrosoacetophenone (INAP, 2-keto-2-phenyl-acetaldoxime) is a novel inducer of plant defense. Oxime functional groups are rare in natural products, but can serve as substrates depending on existing secondary pathways. Changes in the metabolomes of sorghum and tobacco cells treated with INAP were investigated and chemometric tools and multivariate statistical analysis were used to investigate the changes in metabolite distribution patterns resulting from INAP elicitation. Liquid chromatography combined with mass spectrometry (UHPLC-MS) supplied unique chemical fingerprints that were generated in response to specific metabolomic events. Principal component analysis (PCA) together with hierarchical cluster analysis (HCA) and Metabolic Trees were used for data visualization. Orthogonal projections to latent structures discriminant analysis (OPLS-DA) and shared and unique structure (SUS) plots were exploited in parallel to reveal the changes in the metabolomes. PCA indicated that the cells responded differentially to INAP through changes in the metabolite profiles. Furthermore, HCA and Metabolic Trees showed that INAP induced metabolic perturbations in both cell lines and that homeostasis was re-established over time. OPLS-DA-based shared and unique structure (SUS) plots confirmed the results and revealed differences in the metabolites distribution patterns between tobacco and sorghum cells. Chemometric analyses of metabolomic data offers insight into changes in metabolism in response to chemical elicitation. Although similar, the response in sorghum cells was found to be more consistent and well-coordinated when compared to tobacco cells, indicative of the differences in secondary metabolism between cyanogenic and non-cyanogenic plants for oxime metabolism. Electronic supplementary material The online version of this article (doi: 10.1186/2193-1801-3-254) contains supplementary material, which is available to authorized users.
    SpringerPlus 06/2014; 3:254. DOI:10.1186/2193-1801-3-254
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tuberculosis (TB), caused by Mycobacterium tuberculosis is a highly infectious disease, responsible for 1.4 million deaths annually. Unfortunately, the latest reports of treatment outcomes for patients using the current anti-TB drugs are disappointing, considering the high treatment failure rates. This has been ascribed to a number of factors, including, amongst others: (1) variable individual metabolism (including xenobiotic metabolism, drug malabsorption and drugdrug interactions), (2) drug resistance by the infectious organism and (3) non-adherence to the treatment program, especially due to the associated drug side-effects. Despite this however, only two new drugs have been approved by the FDA since 1962. Thus, it is clear that new strategies are needed for the better elucidation of in vivo anti-TB drug mechanisms and their associated side-effects, and the mechanisms by which the infectious organism develops drug resistance. To this end, the relatively new research approach termed ‘metabolomics’, shows promising results through its capacity for identifying new drug markers, or metabolic pathways related to these contributing factors. Metabolomics refers to the unbiased identification and quantification of all metabolites (products of bio-molecular processes) present in a biological system, using highly selective and sensitive analytical methods. The application of metabolomics, for biomarker discovery, is based on the principle that an external stimulus, such as TB disease or infection, an anti-TB drug, or a mutation resulting in drug resistance, may disrupt normal metabolism, altering the overall physiological status of an organism or host, and these metabolic changes are specific to the perturbation investigated and not due to overall inflammation or disease process. Analyses of these altered metabolic pathways, may subsequently shed new light on the mechanisms associated with the causes of treatment failure, and ultimately lead to new treatment strategies which may most likely be aimed at targeting specific metabolic pathways in M. tuberculosis, and/or the genes/proteins associated with these.
    01/2013; 1(4). DOI:10.2174/2213235X113016660006
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tuberculosis (TB) is a chronic wasting inflammatory disease characterized by multisystem involvement, which can cause metabolic derangements in afflicted patients. Metabolic signatures have been exploited in the study of several diseases. However, the serum that is successfully used in TB diagnosis on the basis of metabolic profiling is not by much. Orthogonal partial least-squares discriminant analysis was capable of distinguishing TB patients from both healthy subjects and patients with conditions other than TB. Therefore, TB-specific metabolic profiling was established. Clusters of potential biomarkers for differentiating TB active from non-TB diseases were identified using Mann-Whitney U-test. Multiple logistic regression analysis of metabolites was calculated to determine the suitable biomarker group that allows the efficient differentiation of patients with TB active from the control subjects. From among 271 participants, 12 metabolites were found to contribute to the distinction between the TB active group and the control groups. These metabolites were mainly involved in the metabolic pathways of the following three biomolecules: Fatty acids, amino acids, and lipids. The receiver operating characteristic curves of 3D, 7D, and 11D-phytanic acid, behenic acid, and threoninyl-γ-glutamate exhibited excellent efficiency with area under the curve (AUC) values of 0.904 (95% confidence interval [CI]: 0863-0.944), 0.93 (95% CI: 0.893-0.966), and 0.964 (95% CI: 00.941-0.988), respectively. The largest and smallest resulting AUCs were 0.964 and 0.720, indicating that these biomarkers may be involved in the disease mechanisms. The combination of lysophosphatidylcholine (18:0), behenic acid, threoninyl-γ-glutamate, and presqualene diphosphate was used to represent the most suitable biomarker group for the differentiation of patients with TB active from the control subjects, with an AUC value of 0.991. The metabolic analysis results identified new serum biomarkers that can distinguish TB from non-TB diseases. The metabolomics-based analysis provides specific insights into the biology of TB and may offer new avenues for TB diagnosis.
    Chinese medical journal 01/2015; 128(2):159-68. DOI:10.4103/0366-6999.149188 · 1.02 Impact Factor

Preview

Download
4 Downloads
Available from